PET Centre, Stockholm Brain Institute, Karolinska Institutet, Stockholm, Sweden
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute, Karolinska University Hospital, Stockholm 171 76, Sweden
NeuroSearch Sweden AB, Arvid Wallgrens Backe 20, 413 46, Göteborg, Sweden
References: Aalto, S., Bruck, A., Laine, M., Nagren, K., Rinne, J.O., Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: A positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457 (2005) J Neurosci, 25, pp. 2471-247
Anderson, K.E., Marder, K.S., An overview of psychiatric symptoms in Huntington's disease (2001) Curr Psychiatry Rep, 3, pp. 379-388
Andrews, T.C., Weeks, R.A., Turjanski, N., Gunn, R.N., Watkins, L.H., Sahakian, B., Hodges, J.R., Brooks, D.J., Huntington's disease progression. PET and clinical observations (1999) Brain, 122, pp. 2353-2363
Backman, L., Ginovart, N., Dixon, R.A., Wahlin, T.B., Wahlin, A., Halldin, C., Farde, L., Age-related cognitive deficits mediated by changes in the striatal dopamine system (2000) Am J Psychiatry, 157, pp. 635-637
Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M.C., Dufour, N., Elalouf, J.-M., Brouillet, E., Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II (2008) Hum Mol Genet, 17, pp. 1446-1456
Bergstrom, M., Boethius, J., Eriksson, L., Greitz, T., Ribbe, T., Wideń, L., Head fixation device for reproducible position alignment in transmission CT and positron emission tomography (1981) J Comput Assist Tomogr, 5, pp. 136-141
Bonelli, R.M., Wenning, G.K., Pharmacological management of Huntington's disease: An evidence-based review (2006) Curr Pharm, 12, pp. 2701-2720
Brandt, J., Folstein, S.E., Wong, D.F., Links, J., Dannals, R.F., McDonnell-Sill, A., Starkstein, S., Tune, L.E., D2 receptors in Huntington's disease: Positron emission tomography findings and clinical correlates (1990) J Neuropsychiatry Clin Neurosci, 2, pp. 20-27
Christian, B.T., Lehrer, D.S., Shi, B., Narayanan, T.K., Strohmeyer, P.S., Buchsbaum, M.S., Mantil, J.C., Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task (2006) Neuroimage, 31, pp. 139-152
Clark, M., Cramer III, R., The probability of chance correlation using partial least squares (PLS) (1993) Quant Struct Act Relat, 12, pp. 137-145
Craufurd, D., Snowden, J., Neuropsychological and neuropsychiatric aspects of Huntington's disease (2002) Huntington's Disease, pp. 62-69. , Bates G, Harper P, Jones L, editors. New York: Oxford University Press
DiProspero, N.A., Chen, E.Y., Charles, V., Plomann, M., Kordower, J.H., Tagle, D.A., Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements (2004) J Neurocytol, 33, pp. 517-533
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Trygg, J., Wikström, C., Wold, S., Multi- and megavariate data analysis. PLS (2006) Basic Principles and Applications, , In: Umeå: Umetrics AB
Farde, L., Hall, H., Pauli, S., Halldin, C., Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man (1995) Synapse, 20, pp. 200-208
Farde, L., Suhara, T., Nyberg, S., Karlsson, P., Nakashima, Y., Hietala, J., Halldin, C., A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients (1997) Psychopharmacology (Berl), 133, pp. 396-404
Farde, L., Pauli, S., Hall, H., Eriksson, L., Halldin, C., Hogberg, T., Nilsson, L., Stone-Elander, S., Stereoselective binding of 11C-raclopride in living human brain-A search for extrastriatal central D2-dopamine receptors by PET (1998) Psychopharmacology (Berl), 94, pp. 471-478
Feigin, A., Tang, C., Ma, Y., Mattis, P., Zgaljardic, D., Guttman, M., Paulsen, J.S., Eidelberg, D., Thalamic metabolism and symptom onset in preclinical Huntington's disease (2007) Brain, 130, pp. 2858-2867
Folstein, S., (1989) Huntington's Disease: A Disorder of Families, , Baltimore: Johns Hopkins University Press
Gilbert, A.R., Rosenberg, D.R., Harenski, K., Spencer, S., Sweeney, J.A., Keshavan, M.S., Thalamic volumes in patients with first-episode schizophrenia (2001) Am J Psychiatry, 158, pp. 618-624
Ginovart, N., Lundin, A., Farde, L., Halldin, C., Backman, L., Swahn, C.G., Pauli, S., Sedvall, G., PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease (1997) Brain, 120, pp. 503-514
Gutekunst, C., Norflus, F., Hersch, S., The neuropathology of Huntington's disease (2002) Huntington's Disease, pp. 251-275. , Bates G, Harper P, Jones L, editors. New York: Oxford University Press
Hall, H., Farde, L., Halldin, C., Hurd, Y.L., Pauli, S., Sedvall, G., Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride (1996) Synapse, 23, pp. 115-123
Unified Huntington's disease rating scale: Reliability and consistency (1996) Mov Disord, 11, pp. 136-142. , Huntington Study Group (): -
Jackson, J.E., (1991) A user's guide to principle components, p. 592. , John Wiley and Sons, New York
Kessler, R.M., Whetsell, W.O., Ansari, M.S., Votaw, J.R., de Paulis, T., Clanton, J.A., Schmidt, D.E., Manning, R.G., Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride (1993) Brain Res, 609, pp. 237-243
Lammertsma, A.A., Hume, S.P., Simplified reference tissue model for PET receptor studies (1996) Neuroimage, 4, pp. 153-158
Langer, O., Halldin, C., Dollé, F., Swahn, C.G., Olsson, H., Lundkvist, P., Karlsson, H., Farde, L., Carbon-11 epidepride: A suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors (1999) Nucl Med Biol, 26, pp. 509-518
Lawrence, A.D., Weeks, R.A., Brooks, D.J., Andrews, T.C., Watkins, L.H., Harding, A.E., Robbins, T.W., Sahakian, B.J., The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease (1998) Brain, 121, pp. 1343-1355
Maglione, V., Cannella, M., Martino, T., Blasi, A., Frati, L., Squitieri, F., The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea (2006) Neurosci Lett, 393, pp. 27-30
Meltzer, C.C., Leal, J.P., Mayberg, H.S., Wagner Jr, H.N., Frost, J.J., Correction of PET data for partial volume effects in human cerebral cortex by MR imaging (1990) J Comput Assist Tomogr, 14, pp. 561-570
Mintun, M.A., Raichle, M.E., Kilbourn, M.R., Wooten, G.F., Welch, M.J., A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography (1984) Ann Neurol, 15, pp. 217-227
Modregger, J., DiProspero, N.A., Charles, V., Tagle, D.A., Plomann, M., PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains (2002) Hum Mol Genet, 11, pp. 2547-2558
Okauchi, T., Suhara, T., Maeda, J., Kawabe, K., Obayashi, S., Suzuki, K., Effect of endogenous dopamine on extrastriated [11C]FLB 457 binding measured by PET (2001) Synapse, 41, pp. 87-95
Olsson, H., Farde, L., Potentials and pitfalls using high affinity radioligands in PET and SPECT determinations on regional drug induced D2 receptor occupancy-A simulation study based on experimental data (2001) Neuroimage, 14, pp. 936-945
Pavese, N., Andrews, T.C., Brooks, D.J., Ho, A.K., Rosser, A.E., Barker, R.A., Robbins, T.W., Piccini, P., Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease, a PET study (2003) Brain, 126, pp. 1127-1135
Pavese, N., Politis, M., Tai, Y.F., Barker, R.A., Tabrizi, S.J., Mason, S.L., Brooks, D.J., Piccini, P., Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers (2010) Neurobiol Dis, 37, pp. 356-361
Politis, M., Pavese, N., Tai, Y.F., Tabrizi, S.J., Barker, R.A., Piccini, P., Hypothalamic involvement in Huntington's disease: An in vivo PET study (2008) Brain, 131, pp. 2860-2869
Reading, S.A.J., Dziorny, A.C., Peroutka, L.A., Schreiber, M., Gourley, L.M., Yallapragada, V., Rosenblatt, A., Ross, C.A., Functional brain changes in presymptomatic Huntington's disease (2004) Ann Neurol, 55, pp. 879-883
Reisine, T.D., Fields, J.Z., Stern, L.Z., Johnson, P.C., Bird, E.D., Yamamura, H.I., Alterations in dopaminergic receptors in Huntington's disease (1977) Life Sci, 21, pp. 1123-1128
Roland, P.E., Zilles, K., Brain atlases-A new research tool (1994) Trends Neurosci, 17, pp. 458-467
Rominger, A., Wagner, E., Mille, E., Boning, G., Esmaeilzadeh, M., Wangler, B., Gildehaus, F.J., Cumming, P., Endogenous competition against binding of [18F]DMFP and [18F]Fallypride to dopamine D2/3 receptors in brain of living mouse (2009) Synapse, 64, pp. 313-322
Rosas, H.D., Hevelone, N.D., Zaleta, A.K., Greve, D.N., Salat, D.H., Fischl, B., Regional cortical thinning in preclinical Huntington disease and its relationship to cognition (2005) Neurology, 65, pp. 745-747
Rosas, H.D., Salat, D.H., Lee, S.Y., Zaleta, A.K., Pappu, V., Fischl, B., Greve, D., Hersch, S.M., Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity (2008) Brain, 131, pp. 1057-1068
Strong, T.V., Tagle, D.A., Valdes, J.M., Elmer, L.W., Boehm, K., Swaroop, M., Kaatz, K.W., Albin, R.L., Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues (1993) Nat Genet, 5, pp. 259-265
Suhara, T., Sudo, Y., Okauchi, T., Maeda, J., Kawabe, K., Suzuki, K., Okubo, Y., Farde, L., Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET (1999) Int J Neuropsychopharmacol, 2, pp. 73-82
Squitieri, F., Gellera, C., Cannella, M., Mariotti, C., Cislaghi, G., Rubinsztein, D.C., Almqvist, E.W., Donato, S., Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course (2003) Brain, 126, pp. 946-955
Tang, T.S., Chen, X., Liu, J., Bezprozvanny, I., Dopaminergic signaling and striatal neurodegeneration in Huntington's disease (2007) J Neurosci, 27, pp. 7899-7910
van Oostrom, J.C., Dekker, M., Willemsen, A.T., de Jong, B.M., Roos, R.A., Leenders, K.L., Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease (2009) Eur J Neurol, 16, pp. 226-231
van Vugt, J.P., van Hilten, B.J., Roos, R.A., Hypokinesia in Huntington's disease (1996) Mov Disord, 11, pp. 384-388
Varrone, A., Sjoholm, N., Eriksson, L., Gulya's, B., Halldin, C., Farde, L., Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1639-1650
Volkow, N.D., Gur, R.C., Wang, G.J., Fowler, J.S., Moberg, P.J., Ding, Y.S., Hitzemann, R., Logan, J., Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals (1998) Am J Psychiatry, 155, pp. 344-349
Walker, F.O., Huntington's disease (2007) Semin Neurol, 27, pp. 143-150
Weeks, R.A., Piccini, P., Harding, A.E., Brooks, D.J., Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (1996) Ann Neurol, 40, pp. 49-54
Wold, S., Cross-validatory estimation of the number of components in factor and principal component models (1978) Tecnometrics, 20, pp. 397-405
Young, A.B., Penney, J.B., Starosta-Rubinstein, S., Markel, D.S., Berent, S., Giordani, B., Ehrenkaufer, R., Hichwa, R., PET scan investigations of Huntington's disease, cerebral metabolic correlates of neurological features and functional decline (1986) Ann Neurol, 20, pp. 296-230
Anderson, K. E., Marder, K. S., An overview of psychiatric symptoms in Huntington's disease (2001) Curr Psychiatry Rep, 3, pp. 379-388
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H., Sahakian, B., Hodges, J. R., Brooks, D. J., Huntington's disease progression. PET and clinical observations (1999) Brain, 122, pp. 2353-2363
Bonelli, R. M., Wenning, G. K., Pharmacological management of Huntington's disease: An evidence-based review (2006) Curr Pharm, 12, pp. 2701-2720
Christian, B. T., Lehrer, D. S., Shi, B., Narayanan, T. K., Strohmeyer, P. S., Buchsbaum, M. S., Mantil, J. C., Measuring dopamine neuromodulation in the thalamus: Using [F-18] fallypride PET to study dopamine release during a spatial attention task (2006) Neuroimage, 31, pp. 139-152
DiProspero, N. A., Chen, E. Y., Charles, V., Plomann, M., Kordower, J. H., Tagle, D. A., Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements (2004) J Neurocytol, 33, pp. 517-533
Gilbert, A. R., Rosenberg, D. R., Harenski, K., Spencer, S., Sweeney, J. A., Keshavan, M. S., Thalamic volumes in patients with first-episode schizophrenia (2001) Am J Psychiatry, 158, pp. 618-624
Jackson, J. E., (1991) A user's guide to principle components, p. 592. , John Wiley and Sons, New York
Kessler, R. M., Whetsell, W. O., Ansari, M. S., Votaw, J. R., de Paulis, T., Clanton, J. A., Schmidt, D. E., Manning, R. G., Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I] epidepride (1993) Brain Res, 609, pp. 237-243
Lammertsma, A. A., Hume, S. P., Simplified reference tissue model for PET receptor studies (1996) Neuroimage, 4, pp. 153-158
Lawrence, A. D., Weeks, R. A., Brooks, D. J., Andrews, T. C., Watkins, L. H., Harding, A. E., Robbins, T. W., Sahakian, B. J., The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease (1998) Brain, 121, pp. 1343-1355
Meltzer, C. C., Leal, J. P., Mayberg, H. S., Wagner Jr, H. N., Frost, J. J., Correction of PET data for partial volume effects in human cerebral cortex by MR imaging (1990) J Comput Assist Tomogr, 14, pp. 561-570
Mintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., Welch, M. J., A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography (1984) Ann Neurol, 15, pp. 217-227
Reading, S. A. J., Dziorny, A. C., Peroutka, L. A., Schreiber, M., Gourley, L. M., Yallapragada, V., Rosenblatt, A., Ross, C. A., Functional brain changes in presymptomatic Huntington's disease (2004) Ann Neurol, 55, pp. 879-883
Reisine, T. D., Fields, J. Z., Stern, L. Z., Johnson, P. C., Bird, E. D., Yamamura, H. I., Alterations in dopaminergic receptors in Huntington's disease (1977) Life Sci, 21, pp. 1123-1128
Roland, P. E., Zilles, K., Brain atlases-A new research tool (1994) Trends Neurosci, 17, pp. 458-467
Rosas, H. D., Hevelone, N. D., Zaleta, A. K., Greve, D. N., Salat, D. H., Fischl, B., Regional cortical thinning in preclinical Huntington disease and its relationship to cognition (2005) Neurology, 65, pp. 745-747
Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Pappu, V., Fischl, B., Greve, D., Hersch, S. M., Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity (2008) Brain, 131, pp. 1057-1068
Strong, T. V., Tagle, D. A., Valdes, J. M., Elmer, L. W., Boehm, K., Swaroop, M., Kaatz, K. W., Albin, R. L., Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues (1993) Nat Genet, 5, pp. 259-265
Tang, T. S., Chen, X., Liu, J., Bezprozvanny, I., Dopaminergic signaling and striatal neurodegeneration in Huntington's disease (2007) J Neurosci, 27, pp. 7899-7910
van Oostrom, J. C., Dekker, M., Willemsen, A. T., de Jong, B. M., Roos, R. A., Leenders, K. L., Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease (2009) Eur J Neurol, 16, pp. 226-231
van Vugt, J. P., van Hilten, B. J., Roos, R. A., Hypokinesia in Huntington's disease (1996) Mov Disord, 11, pp. 384-388
Volkow, N. D., Gur, R. C., Wang, G. J., Fowler, J. S., Moberg, P. J., Ding, Y. S., Hitzemann, R., Logan, J., Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals (1998) Am J Psychiatry, 155, pp. 344-349
Walker, F. O., Huntington's disease (2007) Semin Neurol, 27, pp. 143-150
Weeks, R. A., Piccini, P., Harding, A. E., Brooks, D. J., Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (1996) Ann Neurol, 40, pp. 49-54
Young, A. B., Penney, J. B., Starosta-Rubinstein, S., Markel, D. S., Berent, S., Giordani, B., Ehrenkaufer, R., Hichwa, R., PET scan investigations of Huntington's disease, cerebral metabolic correlates of neurological features and functional decline (1986) Ann Neurol, 20, pp. 296-230
Extrastriatal dopamine D 2 receptor binding in Huntington's disease